HYPERPHAGIA IN PRADER-WILLI SYNDROME
Clinical trials for HYPERPHAGIA IN PRADER-WILLI SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HYPERPHAGIA IN PRADER-WILLI SYNDROME trials appear
Sign up with your email to follow new studies for HYPERPHAGIA IN PRADER-WILLI SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New nasal spray aims to curb relentless hunger in rare genetic disorder
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety of a nasal spray called carbetocin for people with Prader-Willi syndrome who experience severe, constant hunger (hyperphagia). About 160 participants who completed a prior study will receive the spray three times daily. The main goal is to mo…
Matched conditions: HYPERPHAGIA IN PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 09:19 UTC
-
New hope for rare hunger disorder: Long-Term drug trial underway
Disease control TerminatedThis study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to see if the d…
Matched conditions: HYPERPHAGIA IN PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 08:59 UTC
-
Nasal spray could curb relentless hunger in rare genetic disorder
Symptom relief OngoingThis study tests a nasal spray called carbetocin to help control the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 170 people aged 5 to 30 will receive either the spray or a placebo for 12 weeks. The main goal is to see if the spray reduces food-seek…
Matched conditions: HYPERPHAGIA IN PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated May 26, 2026 08:59 UTC